The Effect of a Silybin-Vitamin E-Phospholipid Complex on Nonalcoholic Fatty Liver Disease: A Pilot Study

Interuniversity Research Center on Foods, Nutrition and Gastrointestinal Tract (CIRANAD), Unit of Gastroenterology, Second University of Naples, Naples, Italy.
Digestive Diseases and Sciences (Impact Factor: 2.61). 10/2007; 52(9):2387-95. DOI: 10.1007/s10620-006-9703-2
Source: PubMed


Oxidative stress leads to chronic liver damage. Silybin has been conjugated with vitamin E and phospholipids to improve its antioxidant activity. Eighty-five patients were divided into 2 groups: those affected by nonalcoholic fatty liver disease (group A) and those with HCV-related chronic hepatitis associated with nonalcoholic fatty liver disease (group B), nonresponders to treatment. The treatment consisted of silybin/vitamin E/phospholipids. After treatment, group A showed a significant reduction in ultrasonographic scores for liver steatosis. Liver enzyme levels, hyperinsulinemia, and indexes of liver fibrosis showed an improvement in treated individuals. A significant correlation among indexes of fibrosis, body mass index, insulinemia, plasma levels of transforming growth factor-beta, tumor necrosis factor-alpha, degree of steatosis, and gamma-glutamyl transpeptidase was observed. Our data suggest that silybin conjugated with vitamin E and phospholipids could be used as a complementary approach to the treatment of patients with chronic liver damage.

  • Source
    • "Milk thistles, also known as Silybum marianum or silymarin , have been shown to have antioxidant, anti-inflammatory , and antifibrogenic activity along with its ability to help with liver cell regeneration171172173. In a randomized double-blind, controlled trial, silybin (major active constituent of silymarin) combined with vitamin E and phospholipids was shown to significantly improve steatosis [82]. Furthermore, in another multicenter, double-blind clinical trial, 138 patients were randomized to either silybin plus phosphatidylcholine or placebo for 12 months [83]. "
    [Show abstract] [Hide abstract] ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the western world with prevalence of 20–33%. NAFLD comprises a pathological spectrum. Nonalcoholic fatty liver (NAFL) is at one end and consists of simple hepatic steatosis. On the contrary, nonalcoholic steatohepatitis (NASH) consists of steatosis, inflammation, and ballooning degeneration and can progress to cirrhosis. Despite the rising incidence, definitive treatment for NAFLD, specifically NASH, has not yet been established. Lifestyle modification with dietary changes combined with regular aerobic exercise, along with multidisciplinary approach including cognitive behavior therapy, has been shown to be an effective therapeutic option, even without a significant weight loss. Pioglitazone and vitamin E have shown to be most effective in NASH patients. Surgery and weight loss medication are effective means of weight loss but can potentially worsen NASH related fibrosis. Other agents such as n-3 polyunsaturated fatty acids, probiotics, and pentoxifylline along with herbal agent such as milk thistle as well as daily intake of coffee have shown potential benefits, but further well organized studies are definitely warranted. This review focuses on the available evidence on pharmaceutical and nonpharmaceutical therapy in the treatment and the prevention of NAFLD, primarily NASH.
    Full-text · Article · Feb 2016 · Gastroenterology Research and Practice
  • Source
    • "Clinical trials also confirmed that after siliphos treatment, ultrasonographic score for liver steatosis has decreased remarkably in patients with nonalcoholic fatty liver disease. In addition, a significant improvement in liver enzyme levels, indexes of liver fibrosis, and hyperinsulinemia have been observed in siliphos treatment group [101]. The kernels of Prunus armeniaca L are used as a common drug in traditional Chinese medicine. "
    [Show abstract] [Hide abstract] ABSTRACT: Chronic liver dysfunction or injury is a serious health problem worldwide. Chronic liver disease involves a wide range of liver pathologies that include fatty liver, hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. The efficiency of current synthetic agents in treating chronic liver disease is not satisfactory and they have undesirable side effects. Thereby, numerous medicinal herbs and phytochemicals have been investigated as complementary and alternative treatments for chronic liver diseases. Since some herbal products have already been used for the management of liver diseases in some countries or regions, a systematic review on these herbal medicines for chronic liver disease is urgently needed. Herein, we conducted a review describing the potential role, pharmacological studies and molecular mechanisms of several commonly used medicinal herbs and phytochemicals for chronic liver diseases treatment. Their potential toxicity and side effects were also discussed. Several herbal formulae and their biological effects in chronic liver disease treatment as well as the underlying molecular mechanisms are also summarized in this paper. This review article is a comprehensive and systematic analysis of our current knowledge of the conventional medicinal herbs and phytochemicals in treating chronic liver diseases and on the potential pitfalls which need to be addressed in future study.
    Full-text · Article · Dec 2015 · International Journal of Molecular Sciences
  • Source
    • "In these studies, it shows that extract of Milk Thistle (MT) reduced treatment period of acute and chronic hepatitis (Saller et al., 2007). Protective effects of Milk thistle in fatty liver, cirrhosis, viral hepatitis, ischemic liverdamage and cancer was shown previously (Loguercio et al., 2007). Buzzelli and colleagues show that administration of Milk thistle extract "
    [Show abstract] [Hide abstract] ABSTRACT: The present study was carried out to evaluate the effect of Milk thistle (Silybum marianum) in male albino rats. The different groups of animals were administered with Carbon Tetrachloride (CCl 4) to simulate long term liver damage (30 % CCl 4 , 1 mL/kg b.w. in mineral oil at 72 hour intervals). Milk thistle doses of 300, 450 and 600 mg were administered to the CCl 4 treated rats. The effect of Milk thistle on the levels of Aspartate aminotransferase and Alanine Aminotransferase were measured. The Milk thistle produced a significant (p<0.05) hepatoprotective effect by decreasing the levels of enzymes in the blood in a dose dependent manner. Milk thistle in dose of 600 mg showed the most promising potent hepatoprotective property. From those results Milk thistle possesses potent AST and ALT decreasing properties.
    Full-text · Article · Jul 2014
Show more